SCHEMBL209165

SCHEMBL209165

C[C@H]1O[C@@H]([O])[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.63

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.42
CA9 Q16790 2/20 0.42
CA12 O43570 1/20 0.42
FUCA1 P04066 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.34
CA1 P00915 6/20 0.33
GBA1 P04062 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28145005 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL3712080 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL3712541 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL2377987 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL2504504 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL81581 1.00 CA2 (0.42) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL23541364 0.78 FUCA1 (0.48) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL12556709 0.78 FUCA1 (0.48) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL11962132 0.78 FUCA1 (0.48) CA2CA9CA12FUCA1SMN1; SMN2
SCHEMBL22923476 0.78 FUCA1 (0.48) CA2CA9CA12FUCA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486962-A Ginsenoside derivative and preparation method and application thereof 重庆市畜牧科学院 2024-02-02 CN claimed
CN-112204020-B Dioxetane compounds and their use for detecting microorganisms 尼米斯技术公司 2023-11-14 CN claimed
US-20230250123-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS GIIANT PHARMA INC. (CA) 2023-08-10 US claimed
CN-113121619-B Method for catalyzing phenol hydroxyl glycosylation by using organic thiourea 江西师范大学 2023-06-09 CN claimed
US-11649475-B2 Dioxetane compounds and their use for the detection of microorganisms RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-05-16 US claimed
CN-116056713-A Intestinal microbiota bioactive PDE4 inhibitor precursors 吉安特制药公司 2023-05-02 CN claimed
EP-4157853-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS Giiant Pharma Inc. (CA) 2023-04-05 EP claimed
US-20220390459-A1 RAPID, HIGH-INTENSITY CHEMILUMINESCENT DIOXETANES BECKMAN COULTER, INC. 2022-12-08 US claimed
CN-114867716-A Fast, high intensity chemiluminescent dioxetanes 贝克曼库尔特有限公司 2022-08-05 CN claimed
CN-113024627-B Dammarane type triterpenoid saponin compound and preparation method and application thereof 中国科学院昆明植物研究所 2022-03-25 CN claimed
US-20020147317-A1 Fluorogenic compounds and uses therefor 3M INNOVATIVE PROPETIES COMPANY 2002-10-10 US claimed
EP-1204671-A1 FLUOROGENIC COMPOUNDS AND USES THEREFOR 3M Innovative Properties Company (US) 2002-05-15 EP claimed
US-6372895-B1 USEFUL IN ASSAYING FOR BIOLOGICAL ACTIVITY 3M INNOVATIVE PROPERTIES COMPANY 2002-04-16 US claimed
WO-2001029756-A2 AUTOGRID ANALYSIS 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-04-26 WO claimed
WO-2001010881-A1 FLUOROGENIC COMPOUNDS AND USES THEREFOR 3M INNOVATIVE PROPERTIES COMPANY (US) 2001-02-15 WO claimed
EP-0597915-B1 A PROCESS FOR MAKING MORPHINE-6-GLUCURONIDE OR SUBSTITUTED MORPHINE-6-GLUCURONIDE SALFORD ULTRAFINE CHEM & RES (GB) 1998-11-11 EP claimed
US-5633261-A ANTITUMOR AGENTS TORONTO RESEARCH CHEMICALS, INC. (CA) 1997-05-27 US claimed
US-5621087-A ANALGESICS SALFORD ULTRAFINE CHEMICALS AND RESEARCH LIMITED (GB) 1997-04-15 US claimed
EP-0613478-A1 IMMUNOSTIMULATING SWAINSONINE ANALOGS TORONTO RESEARCH CHEMICALS INC. (CA) 1994-09-07 EP claimed
WO-1993009117-A1 IMMUNOSTIMULATING SWAINSONINE ANALOGS TORONTO RESEARCH CHEMICALS INC. (CA) 1993-05-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147317-A1 Fluorogenic compounds and uses therefor NOTUM, WEE1, CPSF7 CA2 4021/4885CA9 4264/4885CA12 3131/4885
US-11649475-B2 Dioxetane compounds and their use for the detection of microorganisms DAXX, LITAF, EDF1 CA2 2934/4885CA9 446/4885CA12 520/4885
US-20230250123-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS PDE4A, PDE4B, PDE4C CA2 1223/4885CA9 494/4885CA12 1776/4885
US-20220390459-A1 RAPID, HIGH-INTENSITY CHEMILUMINESCENT DIOXETANES DAXX, DDX41, PDE8B CA2 1412/4885CA9 220/4885CA12 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.